Search Results - "Goldman, J.M"

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias by Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

“…Several tyrosine kinase inhibitors have activity in Ph-positive chronic and acute leukemia, but resistant disease and unacceptable side effects may limit…”
Get full text

Regional differences in the pituitary distribution of luteinizing hormone in the gonadectomized and proestrous female rat by Goldman, J.M, Stoker, T.E, Murr, A.S, McElroy, W.K, Cooper, R.L

“…Abstract Previous data have shown that regional differences in the presence of anterior pituitary luteinizing hormone (LH) generally correlate with the…”
Get full text

The Third International Congress on Myeloproliferative and Myelodysplastic Syndromes by Silver, R.T, Bennett, J.M, Goldman, J.M, Spivak, J.L, Tefferi, A

“…Abstract This meeting was convened by Richard T. Silver and co-chaired by Jerry L. Spivak. It was held from 27 to 29 October 2005 in Washington, DC. Thirty-one…”
Get full text

Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion by Cohen, B.J., Beard, S., Knowles, W.A., Ellis, J.S., Joske, D., Goldman, J.M., Hewitt, P., Ward, K.N.

“…BACKGROUND: Many reports document the transmission of human parvovirus B19 (B19) infection by clotting factor concentrates manufactured from large plasma…”
Get full text

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia by Hochhaus, A, O'Brien, S G, Guilhot, F, Druker, B J, Branford, S, Foroni, L, Goldman, J M, Müller, M C, Radich, J P, Rudoltz, M, Mone, M, Gathmann, I, Hughes, T P, Larson, R A

“…Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized,…”
Get full text

Impact of Hemochromatosis Gene (HFE) Polymorphisms and Iron Overload on Outcome of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia by Chakrabartty, J, Krishna, R, Balderamos, L.G, Hunt, C, Januszewski, A, Ali, S, Gabriel, I, Marin, D, Apperley, J, Kishore, B, Goldman, J.M, Szydlo, R, Busbridge, M, Rezvani, K

Get full text

Risk Score Predicts Outcome of Second Allogeneic Hematopoietic Stem Cell Transplantation by Rezvani, K, Marin, D, Goldman, J.M, Kanfer, E, MacDonald, D, Dazzi, F, Milojkovic, D, Rahemtulla, A, Sargeant, J, Apperley, J, Szydlo, R

Get full text

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis by Khoury, H J, Kukreja, M, Goldman, J M, Wang, T, Halter, J, Arora, M, Gupta, V, Rizzieri, D A, George, B, Keating, A, Gale, R P, Marks, D I, McCarthy, P L, Woolfrey, A, Szer, J, Giralt, S A, Maziarz, R T, Cortes, J, Horowitz, M M, Lee, S J

“…Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in…”
Get full text

In CML Patients, Residual Disease In Primitive Stem/Progenitor Cells Following Allogeneic Stem Cell Transplantation Is Higher Than After Treatment With Tyrosine Kinase Inhibitors Alone, But Is Still Amenable To GVL Effects by Yong, A.S.M, Keyvanfar, K, Eniafe, R, Savani, B.N, Rezvani, K, Shenoy, A, Koklanaris, E.K, Musse, L, Donohue, T, Le, Q, Goldman, J.M, Barrett, A.J

Get full text

Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles by Shaw, B E, Mayor, N P, Russell, N H, Apperley, J F, Clark, R E, Cornish, J, Darbyshire, P, Ethell, M E, Goldman, J M, Little, A-M, Mackinnon, S, Marks, D I, Pagliuca, A, Thomson, K, Marsh, S G E, Madrigal, J A

“…Disease stage and recipient/donor human leukocyte antigen (HLA) matching are important determinants of outcome in transplantation using volunteer-unrelated…”
Get full text

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib by Marin, D, Gabriel, I H, Ahmad, S, Foroni, L, Lavallade, H de, Clark, R, O'Brien, S, Sergeant, R, Hedgley, C, Milojkovic, D, Khorashad, J S, Bua, M, Alsuliman, A, Khoder, A, Stringaris, K, Cooper, N, Davis, J, Goldman, J M, Apperley, J F, Rezvani, K

“…Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited…”
Get full text

Effects of low subchronic doses of methoxychlor on the rat hypothalamic-pituitary reproductive axis by Goldman, J M, Cooper, R L, Rehnberg, G L, Hein, J F, McElroy, W K, Gray, Jr, L E

“…The pesticide methoxychlor (MXC) is known to possess a weak estrogenic action and has been found to have a number of toxic effects on the rodent reproductive…”
Get more information

333: Cytotoxic T lymphocyte responses to PR1 peptide in CML patients inversely correlate with proteinase 3 and elastase expression but donor PR1-responses determine molecular remission and disease eradication after stem cell transplantation by Yong, A.S.M, Rezvani, K, Savani, B.N, Eniafe, R, Mielke, S, Goldman, J.M, Barrett, J

Get full text

Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007 by Goldman, J M

“…Whereas until 2000 allo-SCT was the recommended treatment for all new patients with CML who were eligible on grounds of age and donor availability, approaches…”
Get full text

Bortezomib Treatment Of Primitive Quiescent CD34+ Cell S In Chronic Myeloid Leukemia Enhances Targeting By In Vitro Expanded Allogeneic Natural Killer Cell S by Yong, A.S.M, Keyvanfar, K, Hensel, N, Eniafe, R, Savani, B.N, Berg, M, Lundqvist, A, Adams, S, Sloand, E.M, Goldman, J.M, Childs, R, Barrett, A.J

Get full text

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia by Bazeos, A, Marin, D, Reid, A G, Gerrard, G, Milojkovic, D, May, P C, de Lavallade, H, Garland, P, Rezvani, K, Apperley, J F, Goldman, J M, Foroni, L, Khorashad, J S

Get full text

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues by Goldman, J M, Green, A R, Holyoake, T, Jamieson, C, Mesa, R, Mughal, T, Pellicano, F, Perrotti, D, Skoda, R, Vannucchi, A M

“…Ph-positive chronic myeloid leukemia (CML) and Ph-negative chronic myeloproliferative diseases (MPDs), characterized in many cases by the presence of the JAK2…”
Get full text

Influence of the formamidine pesticide chlordimeform on ovulation in the female hamster: dissociable shifts in the luteinizing hormone surge and oocyte release by Goldman, J M, Stoker, T E, Perreault, S D, Cooper, R L, Crider, M A

“…The formamidine pesticide chlordimeform (CDF) has been found to interfere with the hormonal control of ovulation in the rat by a presumptive disruption in the…”
Get more information

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy by Yong, A S M, Keyvanfar, K, Eniafe, R, Savani, B N, Rezvani, K, Sloand, E M, Goldman, J M, Barrett, A J

“…The cure of chronic myeloid leukemia (CML) patients following allogeneic stem cell transplantation (SCT) is attributed to graft-versus-leukemia (GVL) effects…”
Get full text

Historique de la leucémie myéloïde chronique : un paradigme de traitement du cancerCet article est entièrement dédié à la mémoire du Professeur John M. Goldman, décédé le 24 décembre 2013. This manuscript is entirely devoted to the memory of sir Professor John M. Goldman, deceased the 24th of December 2013 by Gonon-Demoulian, R., Goldman, J.M., Nicolini, F.E.

“…En deux siècles, les avancées de la médecine et de la recherche médicale ont permis de comprendre les mécanismes physiopathologiques de la leucémie myéloïde…”
Get full text